Pulmonx Corp (LUNG) Q1 2026 Earnings Call Transcript

Why It Matters

The restructuring improves liquidity and positions Pulmonx to restore growth in its core U.S. market while expanding its addressable market through the AeriSeal trial, which could materially boost long‑term valuation.

Key Takeaways

• Q4 revenue $22.6M, down 5% YoY.
• Full-year revenue $90.5M, up 8% YoY.
• Operating expenses cut >10% while maintaining R&D spend.
• New $60M credit facility extends debt to 2031, $20M optional.
• AeriSeal CONVERT2 trial targets 20% market expansion by 2027.

Pulse Analysis

Pulmonx’s latest earnings reveal a mixed performance narrative: while quarterly revenue slipped, the company achieved an 8% full‑year revenue increase, underscoring resilience in its international footprint. The modest decline in U.S. sales reflects internal sales‑force challenges, prompting a comprehensive re‑organization that includes tighter incentive structures and a narrowed focus on high‑impact physician relationships. This operational overhaul aims to restore the momentum that historically powered the Zephyr valve franchise and to lay a more disciplined foundation for future growth.

Financially, Pulmonx has taken decisive steps to strengthen its balance sheet. A $60 million credit facility with an interest‑only, five‑year term not only extends debt maturity to 2031 but also provides an additional $20 million of undrawn capital contingent on revenue milestones. Coupled with a more than 10% reduction in ongoing operating expenses, the company projects a near‑30% reduction in cash burn for 2026, enhancing runway and flexibility for strategic investments. These measures signal to investors that Pulmonx is prioritizing cash efficiency while preserving capital for critical initiatives.

The strategic centerpiece remains the AeriSeal CONVERT2 trial, which targets patients with severe emphysema and collateral ventilation—segments currently underserved by the Zephyr valve. Successful enrollment and eventual approval could expand Pulmonx’s total addressable market by roughly 20%, creating a new revenue stream and reinforcing the company’s position in the pulmonary intervention space. By aligning commercial execution with clinical innovation, Pulmonx is positioning itself for a turnaround that could translate into sustained profitability and higher shareholder value.